A Randomized, Partially-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Effects of a Single Dose of Vorinostat on the QTc Interval in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 03 Aug 2015
At a glance
- Drugs Vorinostat (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 15 Nov 2009 Results reported in Clinical Cancer Research.
- 30 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.